ArticleViruses2026
Immunization of Foals with Equine Rotavirus A Vaccine Can Stabilize or Increase Rotavirus-Specific Neutralizing Antibody Titers.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite a monovalent G3P[12] ('G3') vaccine being available for horses, equine rotavirus A (ERVA) is still the predominant infectious pathogen causing diarrhea in foals in the United States of America (U.S.). Previous research has shown that maternal neutralizing antibody (NAb) titers are too high and will interfere with the vaccination of foals at 30 and 45 days of age. We aimed to determine if it is possible to increase NAb titers in foals through vaccination before they are vulnerable to ERVA infection. We immunized two foals with the commercially available vaccine (G3) at solely three months of age and seven foals at both two and three months of age, respectively. Two mock foals were vaccinated with saline buffer in this study. The dams of these foals were not vaccinated during their gestation period. All pre-vaccination G3 and G14P[12] ('G14') NAb titers in this foal cohort were 256 or lower. Following vaccination, NAb titers in foals were increased up to 1024 against G3 and up to 512 against G14 viruses, respectively. Interestingly, ERVA NAb titers either increased or stabilized in immunized foals depending on the pre-vaccination NAb titer, which contrasts with unvaccinated foals showing a rapid decline in NAb titers over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.